273 F. Supp. 3d 573
D. Md.2017Background
- Plaintiffs (stock purchasers) sued Northwest Biotherapeutics, Inc. (NW Bio) and CEO Linda F. Powers for alleged securities fraud relating to public statements about clinical trials of DCVax-L and DCVax-Direct during Jan 13, 2014–Aug 21, 2015.
- Core allegations: 13 (treated as 14) public statements (press releases, investor presentations, SEC filings) overstated efficacy and mischaracterized trial design, interim analyses, and “information arm” (compassionate-use) results.
- Adverse market disclosures cited by Plaintiffs: critical media articles in June–July 2014 and an FDA clinical hold on Aug 21, 2015, after which NW Bio stock fell.
- Legal claims: violation of Rule 10b-5/§ 10(b) (material misrepresentations/omissions, scienter, loss causation) and § 20(a) (controlling-person liability).
- The district court evaluated the amended complaint under Rule 12(b)(6) with PSLRA and Rule 9(b) heightened pleading standards and granted defendants’ motion to dismiss without prejudice, concluding plaintiffs failed to plead actionable misstatements/omissions and failed to plead a strong inference of scienter.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Actionable falsity/omission for DCVax-Direct case reports | NW claimed tumor necrosis/shrinkage; plaintiffs say results were unsubstantiated, anecdotal, cherry-picked, and could be due to needle trauma or non-RECIST responses | Statements were accurate descriptions of preliminary case data and expressly qualified as early/limited; no duty to disclose every possible confounder | Dismissed — plaintiffs pleaded disagreement with methodology/opinion, not falsity or a materially misleading omission |
| Misleading statements about DCVax-L Phase III design/enhancements | Plaintiffs say changes (p-value targeting, adding patients/events) were goal-post moving to mask weak results | Descriptions ("enhancements," statistical cushion) were truthful or non-actionable puffery and reflect permissible judgment calls | Dismissed — semantic disagreements and methodological disputes are not securities fraud |
| Interim DSMB efficacy analysis and "information arm" results | Plaintiffs allege DSMB efficacy review was completed/withheld and compassionate-use results were biased/incorrectly tabulated | Defendants lacked involvement in DSMB interim process; statements accurately noted pending efficacy review and clearly described information-arm limits | Dismissed — plaintiffs offer speculation and expert conjecture, not facts showing concealment or misleading omissions |
| Scienter and Section 20(a) control-person liability | Plaintiffs claim Powers knew or recklessly ignored adverse data and had motive (personal financial benefit, raising capital) | Position/access, optimism, or desire to raise capital do not show intent or severe recklessness; no specific facts show Powers knew statements were false | Dismissed — no strong, cogent inference of scienter; §20(a) derivative and dismissed because §10(b) fails |
Key Cases Cited
- Ashcroft v. Iqbal, 556 U.S. 662 (pleading must state plausible claim)
- Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308 (PSLRA strong-inference scienter standard)
- Matrixx Initiatives, Inc. v. Siracusano, 563 U.S. 27 (no broad affirmative duty to disclose every potentially material item; omission actionable only when needed to make statements not misleading)
- Cozzarelli v. Inspire Pharm., Inc., 549 F.3d 618 (4th Cir.) (apply Tellabs in securities fraud/scienter analysis)
- Zak v. Chelsea Therapeutics Int’l, Ltd., 780 F.3d 597 (4th Cir.) (contrast: scienter found where defendants concealed adverse FDA expectations and mischaracterized regulatory feedback)
- Longman v. Food Lion, Inc., 197 F.3d 675 (4th Cir.) (distinguishing factual misstatements from puffery/opinion)
- In re Rigel Pharm., Inc. Sec. Litig., 697 F.3d 869 (9th Cir.) (disagreement over methodology does not establish falsity)